Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K

CHAMPIONS ONCOLOGY, INC.

Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.
FY2024 revenue $50.2M (-7% YoY); FY adjusted EBITDA loss $3.9M vs loss $1.3M prior year.
Q4 gross margin 48% (pharmacology services 49%); FY gross margin 41% vs 45% prior year.
Cash $2.6M, no debt; stock repurchase program paused; Corellia AI unit seeking external capital.
Q4 operating loss $190K narrowed from $2.5M prior year; cost-cutting measures improving bottom line.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.